Utah Medical Products (UTMD) Cash from Financing Activities (2010 - 2026)

Utah Medical Products' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 73.64% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was -$9.2 million, a 61.74% increase from a year earlier, with the FY2025 full-year figure at -$12.3 million, up 48.24% from the prior year.
• Cash from Financing Activities advanced to -$1.1 million in Q1 2026 per UTMD's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $19000.0 in Q1 2022 and bottomed at -$7.7 million in Q4 2024.
• The 5-year median for Cash from Financing Activities is -$1.6 million (2025), against an average of -$2.8 million.
• Across the five-year window, Cash from Financing Activities soared 102.0% in 2022 and slumped 5621.05% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$920000.0 in 2022, then declined by 16.41% to -$1.1 million in 2023, then tumbled by 623.34% to -$7.7 million in 2024, then jumped by 74.56% to -$2.0 million in 2025, then surged by 43.33% to -$1.1 million in 2026.
• Per Business Quant, the three latest UTMD Cash from Financing Activities figures stand at -$1.1 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.6 million (Q3 2025).